A World Without Infectious Disease

A new era

We are developing a broad portfolio of product candidates that are designed to combat infectious diseases and other serious conditions, creating medicines that will have a meaningful impact on people around the world.

Hepatitis B

VIR-2218 + PEG-IFN-α

Collaborator:
Alnylam
Treatment Type:
Treatment
Phase:
Phase 2,100%

VIR-3434 ± VIR-2218 ± PEG-IFN-α1

Collaborator:
Alnylam
Treatment Type:
Treatment
Phase:
Phase 2,100%

VIR-2218 + BRII-179

Collaborator:
Alnylam / Brii Biosciences
Treatment Type:
Treatment
Phase:
Phase 2,100%

VIR-2218 + TLR82 + PD-13

Collaborator:
Alnylam / Gilead
Treatment Type:
Treatment
Phase:
Phase 2,100%

Hepatitis Delta

VIR-2218 + VIR-3434

Collaborator:
Alnylam
Treatment Type:
Treatment
Phase:
Phase 2,100%

Influenza A

VIR-2482 (Influenza A)

Treatment Type:
Prophylaxis
Phase:
Phase 2,100%

VIR-2981 (Influenza A+B)*

Collaborator:
GSK
Treatment Type:
Prophylaxis
Phase:
Pre-clinical,100%

HIV

VIR-1388

Collaborator:
BMGF, NIAID and HVTN**
Treatment Type:
Treatment
Phase:
Phase 1,100%

COVID-19

Sotrovimab***

Collaborator:
GSK
Treatment Type:
Treatment Early
Phase:
Authorized,100%

VIR-7229

Treatment Type:
Prophylaxis
Phase:
Pre-clinical,100%

RSV/MPV

VIR-8190*

Collaborator:
GSK
Treatment Type:
Prophylaxis
Phase:
Pre-clinical,100%

Pre-cancerous HPV lesions

VIR-1949

Treatment Type:
Treatment
Phase:
Pre-clinical,100%


1: MARCH trial (Part B), PREVAIL platform trial (THRIVE/STRIVE sub-protocols)
2: GS-9688
3: nivolumab
* Per the collaboration agreement announced in February 2021, Vir and GSK are continuing to advance new monoclonal antibody therapeutics for influenza and other respiratory viruses, including RSV
** Bill and Melinda Gates Foundation, National Institute of Allergy and Infectious Diseases, and HIV Vaccine Trials Network
*** Sotrovimab for early treatment by IV currently has marketing approval, temporary authorization or emergency use authorization in >40 countries. In April 2022, the FDA deauthorized sotrovimab‘s use in all US regions.

Collaborations to advance our technologies and enable global access

We are collaborating with leading companies and organizations to advance our innovative technologies and to enable global access to our future medicines, including:

gsk logo

alnylam logo

BriiBio logo

bill and melinda gates logo

Institute for Research in Biomedicine logo

OHSU logo